908 Devices バランスシートの健全性
財務の健全性 基準チェック /66
908 Devicesの総株主資本は$126.8M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$197.5Mと$70.8Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$101.53m |
| エクイティ | US$126.77m |
| 負債合計 | US$70.77m |
| 総資産 | US$197.54m |
財務の健全性に関する最新情報
Recent updates
Seeking Alpha • Aug 12
908 Devices: Mission Critical Devices Drive Growth
Summary 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M. Valuation remains reasonable at 5.5x forward P/S, supported by a $101.5M cash position, no debt, and narrowing EBITDA losses. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 12
MASS: Index Removals Will Set Up A Future Repricing Opportunity
Analysts have updated their fair value estimate for 908 Devices from $12.00 to $14.00, reflecting revised assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for 908 Devices 908 Devices was dropped from the Russell 2500 Growth Benchmark, according to index classification data.
ナラティブ更新 • Jun 18
MASS: Raised 2026 Revenue Outlook Will Support A Higher Stock Price
Analysts have lifted their price target on 908 Devices stock from $10.00 to $11.00, citing updated assumptions around fair value, revenue growth, discount rate and future P/E that they consider better aligned with the company's current outlook. What’s in the News for 908 Devices 908 Devices raised its full year 2026 revenue guidance, according to a key developments summary.
ナラティブ更新 • Jun 03
MASS: Raised 2026 Revenue Outlook Will Support Higher Future P/E Multiple
Analysts have modestly adjusted their price targets on 908 Devices, reflecting updated assumptions for a fair value of $10.00, a slightly higher discount rate, marginally stronger projected revenue growth, a softer profit margin outlook, and a higher future P/E of about 70x. What's in the News 908 Devices raised its full year 2026 revenue guidance to a range of $67.0 million to $70.0 million.ナラティブ更新 • May 12
MASS: Raised 2026 Revenue Guidance Will Support Higher Earnings Multiple
Analysts have reset their price target on 908 Devices to $10.00 from $8.00, citing updated assumptions around revenue growth, profitability, and future P/E that feed into a higher fair value estimate and a modestly higher discount rate. What's in the News 908 Devices raised full year 2026 revenue guidance to a range of $67.0 million to $70.0 million, compared with 2025 revenue, with the range described as representing 19% to 25% growth (Corporate Guidance: Raised).分析記事 • Jan 23
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
Those holding 908 Devices Inc. ( NASDAQ:MASS ) shares would be relieved that the share price has rebounded 29% in the...分析記事 • Nov 12
Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. ( NASDAQ:MASS ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Sep 20
908 Devices Inc.'s (NASDAQ:MASS) Share Price Not Quite Adding Up
When close to half the companies in the Electronic industry in the United States have price-to-sales ratios (or "P/S...分析記事 • Aug 07
908 Devices Inc. (NASDAQ:MASS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGM:MASS 1 Year Share Price vs Fair Value Explore 908 Devices's Fair Values from the Community and select yours...ナラティブ更新 • Aug 06
US Federal And International Funding Will Expand Global Analysis Markets
The notable increase in 908 Devices’ price target reflects improved outlook due to higher expected revenue growth and an expanded forward P/E, raising the consensus fair value from $6.50 to $9.00. What's in the News 908 Devices raised its 2025 revenue guidance to $54–56 million (13–17% growth), up from prior guidance of $53–55 million.分析記事 • Jun 11
908 Devices Inc.'s (NASDAQ:MASS) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, 908 Devices Inc. ( NASDAQ:MASS ) shares have been powering on, with a gain of 26% in the...
新しいナラティブ • Apr 06
The New Handheld Mass Spectrometer Launch Will Expand Market Reach
Divesting the desktop bioprocessing portfolio boosts cash reserves, streamlines operations, and is expected to enhance margins and cash flow in future years.Seeking Alpha • Mar 06
908 Devices Makes Key Divestiture (Rating Upgrade)
Summary 908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year. Read the full article on Seeking Alpha分析記事 • Mar 05
908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors
The 908 Devices Inc. ( NASDAQ:MASS ) share price has done very well over the last month, posting an excellent gain of...分析記事 • Nov 15
Earnings Update: 908 Devices Inc. (NASDAQ:MASS) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on 908 Devices Inc. ( NASDAQ:MASS ), given that the company fell short...Seeking Alpha • Sep 08
908 Devices: Key Investor Now Selling
Summary ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise concerns about future capital needs. The stock's low valuation compared to peers is a positive, but ongoing sales by ARK Invest could exert further downward pressure. Read the full article on Seeking Alpha分析記事 • Aug 16
Why We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
To the annoyance of some shareholders, 908 Devices Inc. ( NASDAQ:MASS ) shares are down a considerable 29% in the last...分析記事 • Mar 30
We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Dec 18
Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
When you see that almost half of the companies in the Electronic industry in the United States have price-to-sales...財務状況分析
短期負債: MASSの 短期資産 ( $132.0M ) が 短期負債 ( $49.4M ) を超えています。
長期負債: MASSの短期資産 ( $132.0M ) が 長期負債 ( $21.4M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: MASSは負債がありません。
負債の削減: MASS負債比率が11.8%であった 5 年前と比べて負債がありません。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: 利益は出ていないものの、 MASSは現在のプラスの フリーキャッシュフロー レベルを維持すれば、3 年以上は十分な キャッシュランウェイ を有しています。
キャッシュランウェイの予測: MASSは利益は出ていませんが、フリーキャッシュフローがプラスで年間13.5 % 減少しているにもかかわらず、3 年以上は十分なキャッシュランウェイがあります。
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/13 13:25 |
| 終値 | 2026/08/13 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
908 Devices Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Puneet Souda | Leerink Partners LLC |
| Max Masucci | Roth Capital Partners |
| Daniel Arias | Stifel, Equities Research |